Propanc Biopharma, INC S-1 registration statements

Propanc Biopharma, Inc. has filed an S-1 registration statement to allow a selling stockholder to resell up to 2.5 million shares of its common stock.

Propanc Biopharma, Inc. has filed an S-1 registration statement to allow for the resale of up to 15,000,000 shares of its common stock by Hexstone Capital LLC.

Propanc Biopharma, a development-stage cancer treatment company, reported significant losses and a going concern warning, despite recent patent filings and capital raises.

Propanc Biopharma, a development-stage healthcare company, filed an S-1 registration statement for the resale of up to 7,000,000 shares of common stock by a selling stockholder, with its stock trading at $0.39 per share on Nasdaq.

Propanc Biopharma, a development-stage oncology company, reported substantial net losses and negative cash flows, raising significant doubt about its ability to continue as a going concern, despite recent capital raises.

Propanc Biopharma, a development-stage oncology company, is seeking to raise $4.6 million through a public offering of 1 million common shares at $5.00 per share and list on Nasdaq, despite reporting a $54.85 million net loss for the nine months ended March 31, 2025, and facing substantial doubt about its ability to continue as a going concern.

Propanc Biopharma, Inc. has filed an amended S-1 registration statement to offer 1,000,000 shares of common stock and allow for the resale of 3,091,500 shares by existing stockholders, as the company grapples with a significantly increased net loss of $54.85 million and substantial doubt about its ability to continue as a going concern.

Propanc Biopharma amends its registration statement to offer common stock instead of units, targeting a Nasdaq listing to enhance market visibility.

Propanc Biopharma updates its registration statement to revise the number of units being offered in its public offering.

Propanc Biopharma aims to raise capital and list on the Nasdaq through a unit offering consisting of common stock and warrants.

Propanc Biopharma aims to raise capital and transition to the Nasdaq Capital Market through a unit offering, each unit containing a share of common stock and a warrant.

Propanc Biopharma is offering 1,500,000 units, each comprising one share of common stock and one warrant, aiming to raise approximately $6 million for working capital and general corporate purposes.